A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 459 participants.
Also called NCT02547935
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 459 participants
- Sponsor
- Registry
-
NCT02547935
-
- Other papers using this trial's data
- Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
- Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Japan, Mexico, South Africa, South Korea, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT02547935. Randomized; double masking; primary purpose treatment. Start 2015-09-21 (actual); primary completion 2018-05-18 (actual). Results posted on 2019-06-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
- Condition
- Type 2 Diabetes Mellitus, CKD (chronic kidney disease) and Albuminuria
- Intervention (Drug)
- Dapagliflozin 10 mg
- Intervention (Drug)
- Saxagliptin 2.5 mg
- Intervention (Drug)
- Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02547935- Content hash
27e10bc65f5c445d9a456d78581d7ef7ca4e69204a3c7fc83c9d7e6b48b545c7